- Home
- BVN vs PODD Comparison
BVN vs PODD Comparison
Compare BVN & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$33.87
HOLD
Current Price
$132.85
Company Overview
Basic Information| Metric | BVN | PODD |
|---|---|---|
| Founded | 1953 | 2000 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 10.2B |
| IPO Year | 1997 | 2007 |
Fundamental Metrics
Financial Performance| Metric | BVN | PODD |
|---|---|---|
| Price | $33.87 | $132.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 21 |
| Target Price | $44.00 | ★ $341.48 |
| AVG Volume (30 Days) | 959.9K | ★ 1.6M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.67 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $29.99 | $24.55 |
| Revenue Next Year | N/A | $19.18 |
| P/E Ratio | ★ $21.78 | $51.66 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $19.55 | $126.40 |
| 52 Week High | $44.67 | $354.88 |
Technical Indicators
Market Signals| Indicator | BVN | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 33.98 |
| Support Level | $32.60 | $126.40 |
| Resistance Level | $36.66 | $153.33 |
| Average True Range (ATR) | 1.36 | 5.01 |
| MACD | -0.20 | -0.62 |
| Stochastic Oscillator | 17.39 | 1.22 |
Price Performance
Historical Comparison BVN
PODD
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.